Pharmaceuticals company Dr. Reddy's Laboratories announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenues rose 20% YoY to Rs 85,060 million in Q4FY25. Gross margin declined to 55.6% vs 58.6% in Q4FY24. SG&A; expenses increased 17% YoY to Rs 24,055 million, flat QoQ. R&D; expenses stood at Rs 7,258 million (8.5% of revenues). EBITDA reached Rs 24,749 million, at 29.1% of revenues. Profit before tax rose 25% YoY to Rs 20,054 million. PAT (attributable to equity holders) grew 22% YoY to Rs 15,939 million. FY25 Financial Highlights: Revenues grew 17% YoY to Rs 3,25,535 million in FY25. Gross margin remained steady at 58.5% vs 58.6% in FY24. SG&A; expenses rose 22% YoY to Rs 93,870 million. R&D; expenses were Rs 27,380 million, forming 8.4% of revenues. EBITDA stood at Rs 92,133 million, or 28.3% of revenues. Profit before tax increased 7% YoY to Rs 76,784 million. PAT (attributable to equity holders) rose 2% YoY to Rs 56,544 million. G V Prasad, Co-Chairman & MD, said: "We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the U.S. and the integration of the acquired NRT business. We will continue to strengthen and grow our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth opportunities." Result PDF